Suman S, Parghane RV, Joshi A, et al. - In metastatic castration-resistant prostate cancer (mCRPC) patients, significant improvements in their symptomatic response, progression-free survival (PFS), and overall survival (OS) were achieved with the combination of ¹⁷⁷ Lu-PSMA-617 radioligand therapy (PRLT) and abiraterone acetate (AA) therapy vs ¹⁷⁷ Lu-PSMA-617 PRLT monotherapy.

• This study involved mCRPC patients who underwent at least one cycle of ¹⁷⁷ Lu-PSMA-617 PRLT with or without AA therapy.

• Two major groups were formed: Group 1 received only ¹⁷⁷ Lu-PSMA PRLT and Group 2 was administered combined ¹⁷⁷ Lu-PSMA PRLT + AA therapy.

• Total 58 mCRPC patients (Group 1, 38 patients and Group 2, 20 patients) were analyzed.

• Similar clinical and demographic features were revealed on comparing the two groups.

• Comparison for treatment outcome revealed significant p value for symptomatic responders (58% in Group 1 vs 85% in Group 2), median PFS (7 months in Group 1 vs not reached in Group 2), and median OS (8 months in Group 1 vs 16 months in Group 2), with better result in Group 2 for these variables.

• Total seven patients (five in Group 1 and two in Group 2) suffered transient hematological toxicity of Grades 1 and 2.